 |
| Modules | |
| Google | |
|
These ads help pay for the upkeep of our site. They are automatically served by Google and are not affiliated with This is MS. | |
| Languages | |
|
Select Interface Language:
| |
| Who's Online | |
There are currently, 205 guest(s) and 9 member(s) that are online.
You are Anonymous user. You can register for free by clicking here | |
| Next Step | |
| Donations | |
|
To remain unbiased, This is MS does not accept corporate sponsorships. Therefore, we must rely on our users to help support us. Please donate to our upkeep if you have the means. Thank you! | |
| |
 | BioMS expands MBP8298 trial to RRMS patients |
 BioMS, developers of the experimental MS therapy known as MBP8298, have now received medical regulatory agency approval to begin a Phase II trial (out of III necessary for approval) to determine the effects of the drug on patients with the relapsing-remitting form of multiple sclerosis. They currently have a Phase III trial investigating the drug's efficacy versus secondary progressive multiple sclerosis-- a noble achievement given the relative dearth of pipeline treatments for that more insiduous form of the illness.
The trial will take place over one year and enroll approximately 200 patients, with the primary goal to ascertain efficacy and safety of MBP8298 versus placebo. Further, the patient pool is selected to be of the type with the specific immunity genes known as HLA-DR2 or HLA-DR4-- which, according to the company, 75% of the MS population has. The reason for this restricted enrollment set is that MPB8298 works by specifically targeting those particular immune system components, and the company believes the drug will be of highest efficacy in the group that has that particular genetic makeup. Unlike many of the drugs now in development for MS, MBP8298 is administered intravenously.
Click "read more" for the company's press release on this news item...
Advertisement
Official Press Release
BioMS Medical Receives Regulatory Approval For Phase II Relapsing -Remitting Multiple Sclerosis Trial
EDMONTON, Alberta, May 16, 2006 - BioMS Medical Corp (TSX: MS), a leading developer of products for the treatment of multiple sclerosis (MS), announced that it has received regulatory approval to initiate a phase II human clinical trial to investigate the efficacy and safety of MBP8298 in patients with relapsing-remitting multiple sclerosis (RRMS) in the first of several European countries. Patient enrollment is targeted to commence in the third quarter of this year and BioMS anticipates up to 30 sites will participate.
The trial is a 12 month, double blind, placebo-controlled trial and will enroll up to 215 RRMS patients. The trial will be followed by a 15 month active treatment open label extension period. The primary objective of the study is to demonstrate efficacy and safety of MBP8298 versus placebo in patients who are positive with immune response genes HLA-DR2 or HLA-DR4. Patients with the immune response genes, HLA-DR2 or HLA-DR4, account for up to 75% of the MS patient population.
“In addition to our on-going phase III trial for secondary-progressive MS (SPMS), expanding our clinical program into RRMS is significant as the combined patient population for these two indications represent approximately 90% of all MS patients,” said Kevin Giese, President of BioMS Medical.
About Multiple Sclerosis
Multiple sclerosis (MS) is thought to affect as many as 2.5 million people worldwide, including approximately 75,000 in Canada, 400,000 in the United States and over 450,000 in Western Europe. MS is an unpredictable, at times disabling disease of the central nervous system. The disease attacks the protective myelin covering of the central nervous system, causing inflammation and often destroying the myelin in patches.
About BioMS Medical Corp.
BioMS Medical is a biotechnology company engaged in the development and commercialization of novel therapeutic technologies. BioMS Medical’s lead technology, MBP8298, is for the treatment of multiple sclerosis and is currently in a pivotal phase II/III clinical trial across Canada and Europe. For further information please visit our website at www.biomsmedical.com.
This news release may contain certain forward-looking statements that reflect the current views and/or expectations of BioMS Medical with respect to its performance, business and future events. Such statements are subject to a number of risks, uncertainties and assumptions. Actual results and events may vary significantly.
For more information, please contact:
Tony Hesby
Ryan Giese
Corporate Communications
BioMS Medical Corp.
780-413-7152
780-408-3040 Fax
E-mail: rgiese@biomsmedical.com
Internet: www.biomsmedical.com
James Smith
Investor Relations
416-815-0700 ext. 229
416-815-0080 Fax
E-mail: jsmith@equicomgroup.com
Renmark Financial Communications Inc.
Barry Mire: bmire@renmarkfinancial.com
Christine Stewart: cstewart@renmarkfinancial.com
(514) 939-3989
www.renmarkfinancial.com
|
|
|
|
| |
| Login | |
|
Don't have an account yet? You can create one. As a registered user you have some advantages like theme manager, comments configuration and post comments with your name. | |
| Related Links | |
| Article Rating | |
Average Score: 4.33
Votes: 3
| |
| Options | |
|
|
|
